论文信息 - A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development. - 字舞流文

A European pharmaceutical company initiative challenging the regulatory requirement for acute toxicity studies in pharmaceutical drug development.

David Dreher | Kathryn L Chapman | M. Festag | S. Robinson | V. Nogués | A. Lampo | P. Stei | Claudia Stark | S. Old | J. Delongeas | D. Ockert | N. Pickersgill | Sophie Kervyn | K. Nahas | Elizabeth Donald | Kirsty Quinn | Kev Somers | L. Waterson

[1] A. Takagi,et al. Report 3 : BIOTECHNOLOGY PRODUCTS : SPECIFIC ISSUES AND ICH S6 ( Safety assessment of biotechnology-derived pharmaceutical product.) , 1996 .

[2] G. Zbinden,et al. Significance of the LD50-test for the toxicological evaluation of chemical substances , 1981, Archives of Toxicology.

[3] Sielert Me,et al. A Workshop Report , 1968 .

[4] W. Russell,et al. The Principles of Humane Experimental Technique , 1960 .

[5] John William Trevan,et al. The Error of Determination of Toxicity. , 1927 .

[6] P. Botham. Acute systemic toxicity. , 2002, ILAR journal.